
|Videos|July 9, 2020
Ground-Breaking Data from the Phase III ADAURA Trial
Author(s)Targeted Oncology
A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5































